Key result
In vivo generated CAR T cells reduce cardiac fibrosis after myocardial injury in mice.
Why the study?
CAR T cells have proven effective in cancer treatment, and their potential to reduce fibrosis after myocardial injury was recently explored in a mouse model.
Do in vivo generated CAR T cells reduce fibrosis after myocardial injury in a mouse model?
Do in vivo generated CAR T cells reduce fibrosis after myocardial injury in a mouse model?
In vivo generation of CAR T cells represents a novel experimental strategy to mitigate cardiac fibrosis following myocardial injury.
Not ready for clinical use; leaves open translation of in vivo CAR T cells to human cardiac repair.
Autologous chimeric antigen receptor T cells, which are engineered to bind and kill cells that express a specific antigen, are effective in the treatment of certain cancers. A recent study involving a mouse model shows that CAR T cells can be generated in vivo and may reduce fibrosis after myocardial injury.
No takes yet. Share an insight, caveat, or question.
Scott L. Friedman (2022) studied this question. CAR T cells generated in vivo were shown to reduce cardiac fibrosis after myocardial injury in a mouse model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: